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Objective:Duringmyocardial infarction (MI), a transient decrease of both insulin sensitivity and secretion
triggers stress hyperglycemia, which is followed by a substantial increase in mortality. Recent ﬁndings in
cellular models indicate that HDL may act on glucose homeostasis by improving insulin sensitivity and
secretion. In this study, we explored this potential effect in patients during the acute phase of MI.
Methods: Plasma glucose, insulin and C-peptide were measured at admission in the ﬁrst 24h and on the
ﬁfth day after MI with ST-segment elevation in 183 consecutive non-diabetic patients. Patients were
divided into HDL-C quartiles for the analyses (Q1: <31, Q2: 31–38, Q3: 38–47 and Q4: >47mg/dL). The
Homeostasis Model Assessment version 2 was used to assess insulin sensitivity (HOMA2S) and beta-cell
function (HOMA2B).
Results: On admission, no difference was found between the quartiles in glucose (p =0.6), insulin (p=0.6)
or C-peptide (p=0.5) levels, HOMA2S (p=0.9) or HOMA2B (p=1.0). On the ﬁfth day there was a reduction
in glucose levels whose intensity was directly proportional to the HDL-C quartile (p<0.001). At the same
time, there was a reduction in plasma insulin (p<0.001) and C-peptides (p<0.001) whose magnitude
was inversely proportional to the HDL-C quartile. Consistently, the increase of HOMA2S (p<0.001) and
HOMA2B (p=0.01) were also positively associated with HDL-C levels. Furthermore, plasma HDL-C levels
were inversely and independently associated with blood glucose change during the acute phase.
Conclusion: This study demonstrates the association between low plasma HDL-C levels and increased
duration of stress hyperglycemia during MI and suggests in humans the interaction between HDL and
insulin secretion and sensitivity.. Introduction
Stress hyperglycemia during myocardial infarction (MI) has
een consistently shown to be a strong predictor of mortality
n the short and long term, particularly in non-diabetic patients
1]. As the treatment of hyperglycemia reduces mortality in these
I patients, a causal link has been inferred between these two
ariables [2]. From a mechanistic point of view, the presentation
f hyperglycemia during stress is determined by the imbalance
etween the increase in hepatic production of glucose, the decrease
n insulin sensitivity and the capacity of compensating both by
nhancing insulin secretion [3]. Factors that act in any of these
∗ Corresponding author. Tel.: +55 191 3521 7098; fax: +55 119 3521 8788.
E-mail address: dclandrei@yahoo.com (A.C. Sposito).
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oi:10.1016/j.atherosclerosis.2011.09.044© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
steps are therefore candidates for triggering or intensifying stress
hyperglycemia.
It is well established that during the acute phase of MI, counter-
regulatory factors such as cortisol, catecholamines, and cytokines
are released in response to the stress and favor hepatic glucose
overproduction and peripheral insulin resistance (see Ref. [3] for
more details). However, the wide range of variation in the magni-
tude of stress hyperglycemia during MI and the poor correlation
between hyperglycemia and the change in the secretion of these
counter-regulatory factors, suggest that other modulatory path-
ways are also involved [4,5].
In this context, besides thewell-established role of high-density
lipoprotein (HDL) in reverse cholesterol transport and modulation
of inﬂammation, recent ﬁndings indicate a newpotentialmetabolic
role forHDLas aplayer in themodulationofplasmaglucosehomeo-
stasis. In cell models, it was demonstrated that HDL increases
peripheral glucose uptake through activation of AMP-activated
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of 0.05 was considered statistically signiﬁcant. Statistical analy-32 L.S.F. Carvalho et al. / Athe
rotein kinase (AMPK) in muscle cells [6,7] and insulin secretion
y pancreatic -cells [8–10]. Data in humans are still unavailable.
owever, hypothetically, it is plausible that the plasma concentra-
ion of HDL may be among the factors that modulate the duration
nd intensity of stress hyperglycemia.Hence, thepresent studywas
esigned toexplore theassociationbetweenplasma levels ofHDL-C
nd changes in blood glucose and insulin sensitivity and secretion,
n non-diabetic patients, during the acute phase of MI.
. Methods
.1. Patients
Consecutive non-diabetic subjects (n=183) who were enrolled
nto the ongoing Brasilia Heart Study [11] were selected for the
tudy. Brieﬂy, this is a prospective cohortwith consecutive patients
dmitted with ST-segment elevation MI (STEMI). Inclusion criteria
re as follows: (i) less than 24h after the onset of MI symp-
oms, (ii) ST-segment elevation of a least 1mm (frontal plane)
r 2mm (horizontal plane) in two contiguous leads, and (iii)
yocardial necrosis, as evidenced by increased Creatine Kinase-
B (CK-MB) and troponin levels. The study was approved by the
nstitutional Ethics Committee, and all patients signed an informed
onsent.
.2. Clinical evaluation
Medical evaluation and blood sampling were performed upon
dmission at the emergency department. A standardized inter-
iew was performed to assess medical history, all medications
urrently used, and lifestyle factors. Hypertension was deﬁned as a
epeatedly elevated blood pressure exceeding 140 over 90mmHg
uring hospitalization or regular treatment for hypertension prior
o the MI. Sedentary lifestyle was deﬁned as <30min/day of sports
ctivities. Smoking was deﬁned as using 1 or more cigarette/day
or more than 1 year before the coronary event. The time of
ast meal was recorded and the fasting time was calculated
ased on the interval between the last meal and blood collec-
ion.
.3. Biochemical analyses
The ﬁrst blood sample was drawn at admission in the emer-
ency department within 24h after onset of MI symptoms
nd with a mean fasting time of 474±251min. The fasting
ime was equivalent between the 4 quartiles of HDL-C (p=0.8).
he second sample was collected after 12-h overnight fast-
ng on the ﬁfth day of hospitalization. The following blood
r plasma measurements were performed: glucose (Glucose
OD-PAP, Roche Diagnostics, Mannheim, Germany), total choles-
erol (CHOD-PAP, Roche Diagnostics, Mannheim, Germany),
riglycerides (GPO-PAP, Roche Diagnostics, Mannheim, Germany),
DL cholesterol (HDL-C) (HDL cholesterol without sample pre-
reatment, Roche Diagnostics, Mannheim, Germany), CRP (high-
ensitivity CRP, Cardiophase, Dade Behring, Marburg, Germany),
nsulin (Roche Diagnostics, Mannheim, USA), C-peptide (Immulite
000, Diagnostic Products Corporation, Los Angeles, CA, USA)
nd HbA1c (Variant II, Bio-Rad Laboratories, Hercules, CA,
SA). LDL cholesterol was calculated by the Friedewald for-
ula.
.4. Glucose homeostasis model assessmentThe Homeostasis Model Assessment (HOMA) Calculator version
.2.2 was used to estimate  cell function (HOMA2B) and insulin
ensitivity (HOMA2S) [12]. HOMA2S was based on plasma insulinrosis 220 (2012) 231–236
and HOMA2B on plasma C-peptide. In 2955 non-diabetic subjects
(1498 men; 1457 women) aged between 20 and 90 years from The
National Health and Examination Nutrition Survey (NHANES), the
mean HOMA2B and HOM2S were 93.8±34 and 103.5±48, respec-
tively [13].
Insulin secretion and sensitivity are connected via a negative
feedback loop, where pancreatic -cells compensate for changes
in whole body insulin sensitivity by a proportional and reciprocal
change in insulin secretion in a rectangular hyperbolic function (i.e.
y= constant/x) [14]. Thus, the product ofHOMA2BandHOMA2S, i.e.
the disposition index (DI), remains approximately constant if only
one of these parameters is changed. However, this association is
changed when both parameters are simultaneously changed, such
as when insulin secretion is not sufﬁcient to accomplish insulin
resistance compensation. In order to investigate the existence of
changes in HOMA2B, which may occur independently from the
HOMA2S variation, we evaluated the DI change across HDL-C quar-
tiles.
2.5. Euglycemic–hyperinsulinemic clamp
In order to validate the HOMA2S index during MI stress
condition, euglycemic–hyperinsulinemic clamps were performed
on the ﬁrst and ﬁfth day after MI in a subset of the enrolled
patients (n=26). Brieﬂy, at 7:00A.M. on the day of study, an
intravenous cannula was inserted into an antecubital vein, which
was kept open with a slow saline drip, and the arm was heated
to 50 ◦C to arterialize the blood. A second cannula was inserted
into a contra lateral antecubital vein for infusion of insulin and
glucose. After an equilibration period of 30min, basal samples
were collected for determination of plasma glucose and insulin
concentrations. After that, euglycemic–hyperinsulinemic clamps
were performed by infusing insulin (Novolin R; Novo-Nordisk,
Bagsvaerd, Denmark) for 180min at a rate of 7pmol kg−1 min−1.
Euglycemia (∼100mg/dL) was maintained with a variable-rate
infusion of 50% glucose. Blood glucose levels were determined at
10-min intervals, and glucose infusion rates (GIRs) were adjusted
as needed. Insulin sensitivity index (Si) was deﬁned as the increase
in fractional glucose disappearance per unit increase in plasma
insulin, i.e. insulin action (independent of both glucose and insulin
levels) [15].
2.6. Statistical methods
Enrollednon-diabetic patientswere subdivided into four groups
according the quartiles of HDL-C: HDL-Q1 (<31mg/dL, n=49)
HDL-Q2 (31–38mg/dL, n=46), HDL-Q3 (38–47mg/dL, n=43) and
HDL-Q4 (>47mg/dL, n=45). Analysis of covariance (ANCOVA) was
used to assess the effect of HDL quartiles on insulin, C-peptide,
HOMA2 models and DI. Assumptions of the ANCOVA models
(linearity, normality of distribution and equal variance) were
checked using histograms, normal probability plots and resid-
ual scatter plots. Adjustment for baseline levels, age and sex
were performed for comparison of mean change of blood glucose,
insulin, C-peptide, HOMA2 and DI across HDL quartiles. Multivari-
ate analyses by a binary (dichotomous) logistic regression were
performed to verify the independence of the association between
HDL-C and the change of blood glucose or DI from admission
to the ﬁfth day after MI. Data are presented as mean± standard
deviation for normally distributed data. A two-sided p-valueses were performed using SPSS for Windows version 15.0. The
authors had full access to the data and take responsibility for its
integrity. All authors have read and agreed to the manuscript as
written.
L.S.F. Carvalho et al. / Atherosclerosis 220 (2012) 231–236 233
Table 1
Clinical characteristics of enrolled patients.
HDL-Q1 HDL-Q2 HDL-Q3 HDL-Q4 p
n 49 46 43 45
Age (years) 59±10 60±11 64±13 64±12 0.1
Male (%) 86 87 89 87 0.9
BMI (kg/m2) 27.9±5.0 27.3±4.3 26.1±4.8 26.5±4.2 0.3
Waist circumference (cm) 99±13 98±11 92±10 90±10 0.2
HbA1c (%) 5.9±0.4 5.9±0.4 5.9±0.4 5.9±0.4 0.9
Sedentarity (%) 51 48 49 53 0.9
Smoking habit (%) 36 35 39 39 0.4
Peak of CKMB (u/L) 231±202 245±269 258±235 212±206 0.1
Simvastatin use (%) 76 77 77 79 0.7
Simvastatin dose (mg/day) 28±23 26±25 28±24 25±24 0.7
Beta-blocker use (%) 70 66 63 62 0.7
HDL-Q1=HDL-C<31mg/dL; HDL-Q2=HDL-C 31–38mg/dL; HDL-Q3=HDL-C 38–47mg/dL; and HDL-Q4=HDL-C>47mg/dL; BMI: body mass index; HbA1c: glycosilated
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femoglobin; CKMB: creatine kinase-MB.
. Results
.1. Clinical characteristics and change in plasma lipids
Treatment for STEMI was performed in accordance with cur-
ent guidelines. All patients were treated with tenecteplase,
noxaparin, aspirin, beta blockers, nitrates and, when indicated,
nhibitors of angiotensin-converting enzyme. As shown in Table 1,
o signiﬁcant difference was found in clinical characteristics
etween the participants classiﬁed by quartiles of HDL-C. Table 2
resents the laboratory data on admission and on the ﬁfth
ay of hospitalization. Individuals with higher baseline levels
f HDL-C had a greater reduction in these levels in the ﬁrst
days after MI (0±5 vs. −4±6 vs. −5±5 vs. −11±7mg/dL;
<0.001; ﬁrst to the last quartile, respectively). Similarly, indi-
iduals with higher baseline triglyceride levels had a greater
eduction in these levels (−15±95 vs. −14±96 vs. 15±47
s. 19±51mg/dL; p=0.048; ﬁrst to the last quartile of HDL-C,
espectively). There was also a signiﬁcant reduction of LDL-C
−26±35, p<0.001) but it was equivalent in all HDL-C quartiles
p=0.2)..2. Validation of HOMA2S index during MI
Correlations between SI and HOMA2S measurements were
ade using absolute values (Fig. 1). As depicted in Fig. 1A, there
able 2
aboratorial data in the ﬁrst 24h after MI symptoms onset (admission) and on the 5th da
HDL-Q1 HDL-Q2
LDL-C at admission (mg/dL) 122±40 127±45
LDL-C on the 5th day (mg/dL) 95±37 97±31
HDL-C at admission (mg/dL) 27±4 35±2
HDL on the 5th day (mg/dL) 27±8 31±7
Triglycerides at admission (mg/dL) 202±157 180±135
Triglycerides on the 5th day (mg/dL) 187±119 164±69
Glucose at admission (mg/dL) 123±32 121±38
Glucose on the 5th day (mg/dL) 118±30 108±31
Insulin at admission 20 (11–38) 23 (11–32)
Insulin on the 5th day 12 (7–22) 15 (8–20)
C-peptide at admission (mg/dL) 4 (3–9) 4 (3–7)
C-peptide on the 5th day (mg/dL) 4 (3–7) 4 (3–6)
HOMA2S at admission (%) 29 (14, 51) 27 (18, 48)
HOMA2S on the 5th day (%) 32 (19, 47) 34 (22, 49)
HOMA2B at admission (%) 147 (114, 215) 154 (122, 19
HOMA2B on the 5th day (%) 157 (109, 210) 160 (134, 19
DI at admission 4211 (2595, 6372) 4387 (3201,
DI at the 5th day 4500 (3285, 6167) 5863 (3623,
DL-Q1=HDL-C<31mg/dL; HDL-Q2=HDL-C 31–38mg/dL; HDL-Q3=HDL-C 38–47mg/d
or insulin sensitivity; HOMA2B: homeostasis modeling assessment 2 for insulin secretiowas a signiﬁcant and positive correlation between these twometh-
ods, which were similar in the assessments made on the ﬁrst
(r=0.58; p=0.04) and on the ﬁfth day after MI (r=0.54; p=0.03).
Bland–Altman plots were constructed to identify systematic vari-
ation in the assessment of insulin sensitivity by the two methods.
Plots of the difference between SI andHOMA2S values versusmean
values of both variables (difference plots) demonstrated consis-
tency of the agreement between the two methods in the range of
values found in this study (Fig. 1B).
3.3. Change in plasma glucose homeostasis
As shown in Table 2, therewasno signiﬁcant difference between
groups in the mean plasma glucose, insulin and C-peptide levels at
admission. Accordingly, baseline HOMA2B and HOMA2S were also
equivalent among the quartiles. On the 5th day after MI, plasma
glucose levels fell slightly in patients with low HDL-C and more
intensely in those with higher levels of HDL-C (p<0.001 between
the quartiles). Likewise, there was a signiﬁcant reduction in insulin
(p=0.002 between the quartiles) and C-peptide levels (p<0.001
between the quartiles), which was more accentuated in patients
with higher baseline levels of HDL-C.On the ﬁfth day after MI, the median values of HOMA2S and
HOMA2B increased in all groups, but individuals with higher lev-
els of HDL-C reached higher values (Table 2, p<0.001). As shown
in Table 2, DI was equivalent across HDL-C quartiles at baseline,
y of hospitalization.
HDL-Q3 HDL-Q4 p
126±44 129±48 0.3
95±32 102±47 0.8
43±3 55±7 <0.001
38±8 44±9 <0.001
117±44 104±63 <0.001
132±67 123±49 <0.001
128±29 121±22 0.6
108±27 107±20 0.01
21 (10–35) 24 (11–38) 0.6
9 (6–16) 6 (5–9) 0.002
4 (3–7) 4 (3–7) 0.5
3 (2–5) 2 (1–4) <0.001
30 (18, 50) 32 (19, 53) 0.9
41 (29, 59) 48 (21, 66) <0.001
7) 160 (125, 193) 151 (119, 177) 1.0
8) 172 (138, 225) 173 (132, 212) 0.03
6177) 4466 (3000, 6678) 5355 (3665, 6761) 0.5
7615) 7373 (5332, 9399) 7852 (4891, 9970) 0.003
L; and HDL-Q4=HDL-C>47mg/dL; HOMA2S: homeostasis modeling assessment 2
n; DI: disposition index.
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Big. 1. Correlations between insulin sensitivity responses measured by SI and
OMA2S expressed as absolute values (A). (B) The Bland–Altman difference plot
f SI versus HOMA2S.
ut it was signiﬁcantly different on the 5th day after MI (p=0.003
etween quartiles).
In order to verify the impact of HDL-C variation in modulat-
ng insulin secretion and sensitivity, we divided the HDL-C change
etween the ﬁrst and ﬁfth day in quartiles (Q1: −36 to −8.9mg/dL,
2: −9 to −3.9mg/dL, Q3: −4 to 0mg/dL, and Q4: >0mg/dL). There
as no signiﬁcant association between HDL-C change and the
hange in insulin secretion or sensitivity during the ﬁrst ﬁve days
fter MI onset.
.4. Multivariate analyses
A multivariate analysis was performed to investigate the role
f known modulators of insulin sensitivity that are often present
n individuals with low levels of HDL-C, and whose action can
ndirectly generate the association observed between stress hyper-
lycemia and the levels of HDL-C. We considered as potential
onfounding factors the independent variables: gender, age, seden-
arity, HDL-C, triglycerides, waist circumference, CRP levels above
he 75th percentile, and the presence of hypertension. Since a
trong collinearity exists between HOMA2S and HOMA2B, their
ombination expressed by DI was selected as the dependent vari-
ble for the ﬁrst model. The change in DI (delta DI) from admission
able 3
inary logistic regression considering delta DI >38.3% (Model 1) as dependent variable.
Model 1 B S.E. Wald
Gender (male) 0.088 0.416 0.044
Age (years) −0.033 0.018 3.194
Sedentarity −0.089 0.369 0.059
Waist circumference (cm) 0.031 0.017 3.125
Triglycerides (mg/dL) −0.003 0.002 1.518
Hypertension −0.630 0.399 2.490
HDL-C (mg/dL) 0.068 0.020 12.303
CRP> 75th percentile 0.280 0.419 0.448
Constant −3.234 2.237 2.090rosis 220 (2012) 231–236
to the ﬁfth day after MI above or below the median value (38.3%)
was considered as a qualitative binary variable (Model 1). As shown
in Tables 3 and 4, after logistic regression analysis, HDL-C was pos-
itively and independently associated with a higher delta DI. In a
second model, delta DI was replaced by the presence of a reduc-
tion in blood glucose greater than −15mg/dL from admission to
the ﬁfth day (delta glucose). Plasma HDL-C levels were inversely
and independently associated with delta glucose (Table 3).
4. Discussion
The present study demonstrates that stress hyperglycemia dur-
ing the acute phase ofMI is attenuated in patientswith high plasma
HDL-C. In addition, the study reveals that greater increases in both
insulin sensitivity and the compensatory increase in insulin secre-
tion underlie the drop in blood glucose in these patients.
The hyperinsulinemic–euglycemic clamp is largely considered
the gold standard for assessing insulin sensitivity. The suppression
of hepatic glucose secretion by constant infusion of insulin makes
it possible to estimate the proportion of glucose and insulin needed
to keep glucose levels constant and thus estimate insulin sensitiv-
ity. However, in studies with large sample sizes, the use of clamps
is not feasible because it is expensive, time consuming, and labor
intensive. As an alternative, simpliﬁed tests such as the HOMA2S
index have been used in these larger studies and have been vali-
dated by the hyperinsulinemic–euglycemic clamp in individuals in
stable clinical conditions [16]. For this study, a new revalidation of
HOMA2S was required because the target sample was constituted
of individuals under metabolic stress typical of the acute phase of
MI. Despite the stressful condition, we found a strong correlation
between HOMA2S and SI, which was consistent in both periods of
time, admission and ﬁfth day, and over the range of values found
in the study.
As MI develops, plasma concentrations of norepinephrine, cor-
tisol, glucagon, and cytokines increase within minutes and start
to reduce after the ﬁrst day depending on the severity of the
stress response [3,17]. As commented above, the release of these
counter-regulatory factors leads to increased liver glycogenolysis,
and decreased insulin sensitivity. Accordingly, the median insulin
sensitivity in the ﬁrst 24h of MI, as estimated by HOMA2S, was
about 30%, a value well below that observed in the general popu-
lation of nondiabetic individuals (around 100%) [13]. Also, insulin
sensitivity consistently improved on the ﬁfth day after MI.
As mentioned above and in contrast to what was expected,
i.e. a reciprocal interaction between insulin sensitivity and secre-
tion [14], both HOMA2S, HOMA2B and, consequently, DI indexes
increased from admission to the ﬁfth day, suggesting that both
insulin sensitivity and secretion were improved. Such improve-
ment was more accentuated among individuals with higher HDL-C
concentrations. In fact, recent studies in cell models suggest that
HDL particles can inﬂuence blood glucose homeostasis via multi-
ple actions both dependent and independent of insulin secretion.
p Exp(B) 95% C.I. for Exp(B)
Lower Upper
0.833 1.092 0.483 2.469
0.074 0.968 0.934 1.003
0.809 0.915 0.444 1.884
0.077 1.031 0.997 1.067
0.218 0.997 0.993 1.002
0.115 0.533 0.244 1.165
0.0001 1.071 1.031 1.113
0.503 1.324 0.582 3.008
0.148 0.039
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Table 4
Binary logistic regression considering delta blood glucose <−15mg/dL (Model 2) as dependent variable.
Model 2 B S.E. Wald p Exp(B) 95% C.I. for Exp(B)
Lower Upper
Gender (male) 0.573 0.560 1.050 0.306 1.774 0.592 5.314
Age (years) −0.002 0.024 0.004 0.949 0.998 0.954 1.046
Sedentarity −0.109 0.519 0.045 0.833 0.896 0.324 2.478
Waist circumference (cm) 0.010 0.025 0.150 0.698 1.010 0.961 1.061
Triglycerides (mg/dL) 0.002 0.002 0.484 0.487 1.002 0.997 1.006
Hypertension 0.503 0.553 0.826 0.363 1.654 0.559 4.891
4.875
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CRP>75th percentile 0.596 0.574
Constant −3.791 3.427
n skeletal muscle cells, apolipoprotein (Apo) A-I, a major protein
onstituent of HDL, induces phosphorylation of AMPK and acetyl-
oenzyme A carboxylase (ACC), thus increasing glucose uptake
nd endocytosis [17]. In addition, HDL may also increase insulin
ecretion in pancreatic -cells via direct action by activating the
TP-binding cassette transporter A1 (ABCA1) [9] and via indi-
ect action by inhibiting the activation of the c-Jun NH2-terminal
inase (JNK) pathway induced by oxidized LDL [8]. Fryirs et al.,
10] recently found that both Apo A-I and Apo A-II increase the
roduction and secretion of insulin through a mechanism equally
ependent on ABCA1 and scavenger receptor B1 (SR-B1) trans-
orters in pancreatic -cells.
The increase in cholesterol efﬂux induced by the apolipopro-
eins A-I and A-II is appointed as the likely causal mechanism.
elipidation of cholesterol-enriched cells may facilitate the dock-
ng and fusion of insulin-containing granules from the readily
eleasable pool and thus lead to an increase of insulin secretion
9,10]. In subjects with type 2 diabetes mellitus, intravenous infu-
ion of reconstituted HDL particles sharply reduces plasma glucose
nd increases plasma insulin as compared to administration of a
lacebo [6]. In these individuals, skeletal muscle biopsies demon-
trate increased ACC phosphorylation.
Indirectly, highplasma levels ofHDLcanattenuate the induction
f insulin resistance through its anti-inﬂammatory effects. Indeed,
n vitro studies demonstrate a role of HDL as a buffer mechanism
or oxidative stress and inﬂammation [18]. To date, however, lit-
le is known about the interaction between HDL particles and the
nﬂammatory response during the acute phase of acute coronary
vents.
Despite themechanistic evidenceabove, it is reasonable toques-
ion whether these effects result from the direct action of HDL or
re induced by metabolic and clinical factors commonly found in
ubjects with low HDL plasma levels. For example, plasma HDL
s reduced by age, male gender, increased body weight, hyper-
riglyceridemia, hypertension and inﬂammatory states. All these
haracteristics may inﬂuence glucose homeostasis. To clarify this
ssue, multivariate logistic regression analyses were performed
sing the change of DI or of blood glucose between admission
nd the ﬁfth day as dependent variables. In both models, HDL-
plasma concentration was independently associated with the
mprovement of the acute imbalance of glucose homeostasis.
It is noteworthy tomention that the change in HDL-C during the
rst ﬁve days of hospitalizationwas not associatedwith the change
nbloodglucose, insulin sensitivity or secretion. Yet, although stud-
es are needed to clarify this ﬁnding, it can be inferred from this
tudy that simply increasing or decreasing the HDL concentrations
uring the acute phase of MI does not guarantee the modulation of
ts interaction on glucose homeostasis.Some limitations should be considered when interpreting the
ndings of this study. Despite carrying out multivariate anal-
sis, the study is not able to detect the role of unmeasured
r unknown factors as potential links between HDL levels and0.027 1.064 1.007 1.124
0.299 1.815 0.589 5.596
0.269 0.023
glucose homeostasis. We deﬁned as the main exclusion criterion
the presence of diabetes mellitus identiﬁed by a previous diag-
nosis or, in its absence, by the presence of HbA1c levels greater
than 6.5%, consistently with the report of the World Health Orga-
nization [19]. As the elevation of blood glucose typically occurs in
the acute phase of MI, we could not use blood glucose to improve
the exclusion criterion. However, we repeated the analysis consid-
ering only patients admitted with HbA1c<6.0% (n=123) and we
found the same results. Although there is substantial pathophys-
iological mechanisms underlying the association between HDL-C
levels and the change in insulin sensitivity during MI, it is pos-
sible that individuals who do not yet have glucose intolerance at
normal conditions but who have reduced tolerance to prolonged
hyperglycemic stress manifest low HDL-C as part of their clinical
phenotype. This study is not able to exclude this possibility. Finally,
as the study was conducted in subjects with STEMI, the present
ﬁndings should not be extrapolated to other populations. Never-
theless, these ﬁndings can indeed open the door to debate on how
to use the HDL-C concentrations in plasma, either as a marker or
therapeutic target, in the setting of stress hyperglycemia.
In conclusion, this study provided the ﬁrst evidence in humans
suggesting that low HDL-C is associated with a delayed recov-
ery of stress hyperglycemia, and reduced insulin secretion and
sensitivity induced during acute phase of MI. Taking into consider-
ation the robust association between hyperglycemia and adverse
clinical outcome after MI, this association between HDL-C and glu-
cose homeostasis under acute stress deserves attention and further
exploration.
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